Ipilimumab
نویسندگان
چکیده
منابع مشابه
Ipilimumab
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II for lymphoma and non-small cell lung cancer ...
متن کاملIpilimumab induced digital vasculitis
BACKGROUND Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are becoming a common occurrence. CASE PRESENTATION We describe the first reported patient with small vessel vasculitis, manifested by digital ischemia, following treatment with high do...
متن کاملIpilimumab-induced colonic perforation
Biologic immune modulators such as ipilimumab have demonstrated the efficacy against metastatic melanoma. We present a recent case of a 52-year-old male who initially developed mild colitis following the initiation of ipilimumab treatment for metastatic melanoma. Despite initial improvement with immediate cessation of drug and initiation of high-dose steroid therapy his clinical condition worse...
متن کاملIpilimumab-Induced Neutropenia in Melanoma
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, an...
متن کاملIpilimumab and Bevacizumab in Glioblastoma.
The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade. There is significant evidence supporting its role in the treatment of malignant melanoma, including in patients with brain metastases. The addition of the anti-angi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2014
ISSN: 1538-4047,1555-8576
DOI: 10.4161/cbt.29928